S. Marciniak

发表

Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis

Stanley B. Cohen, Mahboob Rahman, G. Shankar, 2007, Journal of clinical pharmacology.

Reduced inhibition by abciximab in platelets with the PlA2 polymorphism.

M. Mascelli, D. Sane, P. Bray, 2002, American heart journal.

Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.

H. Weisman, R. Jordan, M. Mascelli, 2000, American heart journal.

First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial

W. Stohl, R. Furie, L. Seridi, 2020 .

Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus

Amarnath Sharma, Zhenhua Xu, S. Marciniak, 2020, Clinical Drug Investigation.

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

Y. Wasfi, C. Leonardi, Katherine Li, 2014, The Journal of allergy and clinical immunology.

An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates

R. Jordan, M. Furman, M. Mascelli, 2002, Thrombosis and Haemostasis.

Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach

Honghui Zhou, Zhenhua Xu, S. Marciniak, 2015, Journal of clinical pharmacology.

Binding specificity and associated effects of platelet GP IIb/IIIa inhibitors

N. Chronos, S. Marciniak, M. Nakada, 1999 .

Effect of Ca2+ Chelation on the Platelet Inhibitory Ability of the GPIIb/IIIa Antagonists Abciximab, Eptifibatide and Tirofiban

R. Jordan, M. Mascelli, S. Marciniak, 2001, Thrombosis and Haemostasis.

In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.

M. Mascelli, S. Marciniak, S. Harder, 2001, Thrombosis research.

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

Honghui Zhou, Zhenhua Xu, S. Marciniak, 2016, European Journal of Clinical Pharmacology.

Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition

W. Stohl, R. Furie, M. Cesaroni, 2021, Lupus.

A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects

B. Frederick, Honghui Zhou, J. Marini, 2014, Clinical pharmacology in drug development.

Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector.

B. Frederick, Honghui Zhou, Zhenhua Xu, 2015, Clinical therapeutics.

Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach

Honghui Zhou, Zhenhua Xu, S. Marciniak, 2015, Journal of clinical pharmacology.

Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector.

B. Frederick, Honghui Zhou, Zhenhua Xu, 2015, Clinical therapeutics.

A Phase I, Single and Fractionated, Ascending‐Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects

B. Frederick, J. Getsy, A. Cohen, 2008, Journal of clinical pharmacology.